Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report
Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Lisa Argnani(Istituto di Ematologia di Bologna), Marianna Gentilini(Istituto di Ematologia di Bologna), Camilla Mazzoni(Istituto di Ematologia di Bologna), Flavia Salvatore(Istituto di Ematologia di Bologna), Beatrice Casadei(Istituto di Ematologia di Bologna), Giulia Gabrielli(Hospital of the University of Pennsylvania)
Cited by 0
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523